6 cells (median; 1.5-11.1).
As expected, alemtuzumab caused profound T-cell depletion (by a median of 0.06 Â 10 9 /l versus 7.34 Â 10 9 /l in control) as well as B-cell depletion (by a median of 0 versus 1.86 Â 10 9 /l in control). CD4 þ and CD8 þ lymphocytes were equally eliminated. Alemtuzumab produced a moderate reduction of CFU-GM and BFU-E (by a median of 6.6 versus 5.1, and 10.5 versus 8.4 colony numbers Â 10 4 /ml, respectively). Alemtuzumab also reduced the numbers of monocytes and nonsignificantly the numbers of natural killer (NK) cells. Surprisingly, incubation with alemtuzumab clearly enhanced the growth of CFU-Meg; in median five times more CFU-Meg were observed in samples after incubation with alemtuzumab (Po0.001). Our T-cell repletion experiments show that CD8 þ T cells, as well as CD4 þ T cells play a role in the physiological suppression of megakaryopoiesis. Adding autologous CD8 þ T cells, as well as adding autologous CD4 þ T cells to samples incubated with alemtuzumab led to a reduction in the growth of CFU-Meg. This contrasts with the growth following incubation with alemtuzumab without further intervention. This reduction did not achieve, however, the low levels in the number of CFU-Meg in control samples. A growth of CFU-Meg 90 colony numbers (median; 1-383) was observed after adding CD4 þ T cells, and a growth of 60 colony numbers (median; 1-336) occurred after adding the CD8 þ T cells. The differences between these results were statistically insignificant, whereas statistically significant differences were confirmed when these results were compared with the colony numbers in samples cultivated with alemtuzumab without further intervention (median 236; 2-733), and the colony numbers in control samples (median 43; 2-137). The results of the experiments are summarized in Table 1 .
Based on these findings, we decided to use alemtuzumab in treating a 63-year-old woman suffering from severe and therapyresistant acquired amegakaryocytic thrombocytopenic purpura (AATP). The patient did not show any improvement after 4 weeks of methylprednisolone and cyclosporin A therapy. The patient's bone marrow samples were tested as described above and a remarkable enhancement of CFU-Meg growth (106 CFUMeg/1 ml of bone marrow) was observed in a sample incubated with alemtuzumab compared with the control sample (2.4 CFUMeg/1 ml of bone marrow). Both cyclosporin A and corticosteroid were withdrawn, and upon informed consent signature, the patient received alemtuzumab at a dose of 10 mg three times weekly for 9 weeks. After the third week of administration, alemtuzumab was discontinued for 4 weeks for cytomegalovirus reactivation. The patient's platelets count significantly increased from 10 Â 10 9 /l before treatment to 67 Â 10 9 /l after alemtuzumab administration. The patient is now 9 months free of bleeding and without any hematological treatment.
To the best of our knowledge, this is the first information about CFU-Meg growth stimulation by alemtuzumab and about the treatment of AATP with alemtuzumab. So far, any significant effect of alemtuzumab on human hematopoietic progenitors in vitro has not yet been described. However, the particular effect of alemtuzumab on CFU-Meg has not been studied. 3 Nevertheless, Chakrabarti et al.
1 noted that platelet engraftment was significantly faster in patients receiving alemtuzumab Leukemia (2006) 
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T-cell-depleted grafts than in patients receiving unmanipulated grafts, and Nagler et al. 5 described enhancement of megakaryopoiesis by Campath-1G-treated NK cells.
Cellular and humoral influences of T-lymphocytes on human megakaryocyte colony formation were described in the 1980s. According to Geissler et al., 6 CD4 þ lymphocytes enhance and CD8 þ lymphocytes downregulate megakaryocyte colony formation. However, the results of our experiments suggest that megakaryopoiesis can be physiologically inhibited by CD4 þ as well as CD8 þ T cells. Nonetheless, suppression of megakaryopoiesis by lymphocytes is evidently a complex phenomenon that cannot be explained by simple quantitative changes in individual cell populations alone. Currently, it seems that activated bone marrow CD4 þ T cells are very important for maintaining normal hematopoiesis. 7 Physiological suppression of megakaryopoiesis by T-lymphocytes may be a part of this phenomenon.
AATP is a hematological disorder characterized by severe thrombocytopenia owing to an immunologically induced absence of megakaryocytes in an otherwise normally appearing bone marrow. 8 It can be a primary disorder in itself or can be seen in aplastic anemia, myelodysplastic syndromes and in rheumatoid diseases. In the bone marrow culture of AATP patients, the isolated reduction of CFU-Meg was observed. 8 In conclusion, our results demonstrate that megakaryopoiesis is physiologically suppressed by lymphocytes. Therefore, profound lymphocyte depletion caused by alemtuzumab stimulates megakaryopoiesis in vitro. Moreover, our case report also demonstrates that alemtuzumab can be effective in the treatment of patients with AATP, and perhaps in the treatment of other thrombocytopenias. 
